RedHill Biopharma Ltd. (RDHL) KPIs and segments

RDHLNasdaqPharmaceutical Preparations

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 27, 2026Score 0/30

$0.38−0.01 (-1.60%)

Close on Nov 13, 2026Market cap $1.91MP/E –Yield –

KPIs & segments

Operating metrics and segments that drive RedHill Biopharma's business

RedHill Biopharma's revenue by segment, product and region, plus the counts and sizes it tags in its 10-K and 10-Q filings (XBRL). Each figure links to the filing it came from. A fuller KPI sheet built from earnings releases and presentations is on the way. See the segment tables for a trailing-twelve-month view, or how companies compare on operating metrics.

The chart is empty. Tick the box next to any metric in the table below to plot it — tick several to compare them on one chart.

Metric	Q2 2022	Q2 2021

Commercial Operations($M)	-2.91	-5.47
Research and Development($M)	-3.71	-11.8

Earlier reporting (last reported 2024)1

Earlier reporting (last reported 2021)2

Italic numbers are calculated by StockData from reported figures (hover for the formula). Numbers with a dotted underline are read from the text of earnings releases and presentations; hover to see the exact sentence. Tick a row to add it to the chart above (up to 8 lines).

Methodology and excluded metrics

Core rows come from the segment and revenue-disaggregation notes of 10-K and 10-Q filings (XBRL), linked to each filing. Fourth-quarter figures are the fiscal year less the first nine months (shown in italic).

Data updated 2025-04-10.

See a number that looks wrong?